Phase 1 clinical trial of PQ-203
Latest Information Update: 16 Jun 2025
At a glance
- Drugs ARB 1 6 (Primary)
- Indications Triple negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 16 Jun 2025 New trial record
- 28 May 2025 According to ProteinQure media release, company announced today the close of an $11 million Series A financing round. The proceeds will support the initiation of the trial for PQ203.